Theralase Technologies (TSXV:TLT) Additional Paid-In Capital : C$17.58 Mil(As of Dec. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Additional Paid-In Capital?

Theralase Technologies's quarterly additional paid-in capital increased from Jun. 2024 (C$13.30 Mil) to Sep. 2024 (C$17.18 Mil) and increased from Sep. 2024 (C$17.18 Mil) to Dec. 2024 (C$17.58 Mil).

Theralase Technologies's annual additional paid-in capital increased from Dec. 2022 (C$11.37 Mil) to Dec. 2023 (C$12.49 Mil) and increased from Dec. 2023 (C$12.49 Mil) to Dec. 2024 (C$17.58 Mil).

Theralase Technologies Additional Paid-In Capital Historical Data

The historical data trend for Theralase Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Additional Paid-In Capital Chart

Theralase Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

10.25

10.94

11.37

12.49

17.58

Theralase Technologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															12.49	13.22	13.30	17.18	17.58

Theralase Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Theralase Technologies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

TLTFF:USA TTX:Germany

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

Executives

Matthew Thomas Perraton	Director
Roger John Dumoulin-white	10% Security Holder, Director, Senior Officer
Kristina Maria Hachey	Senior Officer
Arkady Mandel	Senior Officer
Guy John Anderson	Director
Shawn Shirazi	Senior Officer